• Traverse
    • Timmerman Traverse for Damon Runyon 2026
    • Past Climbs (2018-2025)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for Damon Runyon 2026
    • Past Climbs (2018-2025)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
1
Jul
2016

Impressions from the Moonshot, Gilead’s New HCV Drug, & Nobelists Rip Greenpeace

/
Luke Timmerman
/
2
/
All
01 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Jun
2016

Pfizer, GSK, AbbVie Join $51.5M Bet on Computational Drug Discovery Shop, Morphic Therapeutic

/
Luke Timmerman
/
1
/
All, Drugs, Venture Capital
30 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Jun
2016

The VP is Asking for Advice on Cancer. Share Yours Before I Go To Washington

/
Luke Timmerman
/
2
/
All, Cancer, Politics
27 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Jun
2016

Obama Toys With Precision Med Job, Gates Shines Light on Superbugs, & Parker Angles Into CRISPR Trial

/
Luke Timmerman
/
0
/
All
24 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Jun
2016

Going Public at Beaten Down Valuations? The Crossover Hangover

/
Luke Timmerman
/
0
/
All, Finance, Venture Capital
20 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Jun
2016

Opioid Kickbacks Exposed, Infinity Crashes & Merck’s PD-1 Extends Lives

/
Luke Timmerman
/
0
/
All
17 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Jun
2016

The Schreiberians: Where Are They Now?

/
Luke Timmerman
/
0
/
All, People
14 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Jun
2016

BIO Loves Newt: A Backdoor Into a Trump Administration?

/
Luke Timmerman
/
0
/
All, People, Politics
13 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Jun
2016

BIO Jabs Payers, the Sarepta Plot Thickens, & Merck Buys Afferent

/
Luke Timmerman
/
1
/
All
10 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Jun
2016

Silicon Valley Joins the Drug and Device Discovery Party

/
Lisa Suennen
/
0
/
All, Strategy
07 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Jun
2016

Is Bigger Better in Biotech Venture Capital?

/
Luke Timmerman
/
0
/
All, Venture Capital
06 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Jun
2016

ASCO Preview, BioMarin’s Costly DMD Write-Off, & A Superbug Wakeup Call

/
Luke Timmerman
/
0
/
All
03 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Jun
2016

Fantasy Drug Development: Fleshing out a Cool Way to Test Your Wits in the Biopharma Game

/
Kyle Serikawa
/
1
/
All
02 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
May
2016

Regeneron’s Generosity, Minerva’s Breakout, & Sarepta Waits

/
Luke Timmerman
/
1
/
All, People
27 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
May
2016

Sexism in Biotech: Be Aware, and Stay Vigilant

/
Luke Timmerman
/
1
/
All
23 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
May
2016

Genentech Enters the PD-L1 Arena, Theranos in Ashes & the ASCO PR Machine Revs Up

/
Luke Timmerman
/
0
/
All
20 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
May
2016

I-O: Who’s Doing What? (Part 2)

/
Luke Timmerman
/
0
/
All, Cancer, Drugs
19 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
May
2016

Immuno-Oncology: Who’s Doing What?

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
16 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
May
2016

John Oliver’s Rant, the Sid Mukherjee Tempest & A Lung Cancer Mea Culpa

/
Luke Timmerman
/
0
/
All, Drugs
13 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
May
2016

How Distributed R&D Could Spark Entrepreneurship in Biopharma

/
Kyle Serikawa
/
0
/
All, Drugs, Politics
11 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 70 71 72 73 74 … 81 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder